YWYihan Wang

Yihan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yihan Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Kai Huang

    Department of Pharmacology, College of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei Province, China

    1 shared publication
  • Linqi Yang

    Department of Pharmacology, College of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei Province, China

    1 shared publication
  • Meng Li

    Department of Pharmacology, College of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei Province, China

    1 shared publication
  • Meng Wu

    Department of Gastroenterology, Qinhuangdao Beidaihe Hospital, Qinhuangdao, 066199 Hebei Province, China

    1 shared publication
  • Tao Sun

    Department of Pharmacology, College of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei Province, China

    1 shared publication
  • Wenqi Zhang

    Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

    1 shared publication

Latest Publications

  • Retracted
    Open Access

    DDTC Suppresses Ovarian Cancer Development via the PI3K/AKT/mTOR Signaling Pathway

    by Meng Li, Wenqi Zhang, Yihan Wang, Kai Huang, Tao Sun, Zhicong Qiu, Linqi Yang, Meng Wu, Xiaolu Zhang

    In prior research, 6,12-diphenyl-3,9-diazatetraasterane-1, 5, 7, 11-tetracarboxylate (DDTC) has been shown to be an effective inhibitor of the growth of the SKOV3 and A2780 ovarian cancer (OC) cell lines. Flow cytometry analyses indicated that DDTC was able to suppress P-CNA expression at the protein level within OC cells, while RNA-seq indicated that DDTC treatment was associated with marked changes in gene expression profiles within A2780 cells. Molecular docking analyses suggested that DDTC has the potential to readily dock with key signaling proteins including PI3K, AKT, and mTOR. In line with these findings, DDTC treatment inhibited the growth of xenograft tumors in a mouse model system. Such treatment was also associated with reduced p-PI3K/PI3K, p-AKT/AKT, p-mTOR/mTOR, and CyclinD1 (CCND1) expressions and with the increased expression of PTEN in vitro and in vivo. Together, these results suggest that DDTC is capable of readily inhibiting OC development at least in part via targeting and modulating signaling via the PI3K/AKT/mTOR axis.